Open Orphan #ORPH – World’s first Covid-19 human challenge study to expand July 14, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, is continuing to work with the UK Government to inoculate up to 20 further volunteers as part of the world’s first COVID-19 characterisation study. As part of the characterisation study, researchers aimed to identify a dose of COVID-19 that…

Open Orphan #ORPH – £3m COVID-19 challenge virus manufacturing contract for hVIVO based on new COVID-19 variants May 9, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, has signed a contract with Imperial College London, as part of a Wellcome Trust funded initiative to manufacture a SARS-CoV-2 challenge virus. The contract is worth £3 million and under this agreement hVIVO will develop a new SARS-CoV-2…

Open Orphan #ORPH – COVID-19 Human Challenge Programme update March 25, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces an update in the world’s first COVID-19 characterisation study. Following Research Ethics Committee approval on 17 February 2021, hVIVO, a subsidiary of Open Orphan, began the study at the Royal Free London NHS Foundation Trust earlier this month. The first three volunteers have now successfully completed…

Open Orphan #ORPH – Ethics approval – COVID-19 Human Challenge Study February 17, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces the world’s first COVID-19 characterisation study has received approval from a specially convened Research Ethics Committee (“REC”). This news follows the announcement on 20 October 2020 of Open Orphan subsidiary hVIVO’s contract with the UK Government to develop a COVID-19 human challenge study model. The…

Open Orphan #ORPH – World’s first Covid-19 human challenge study to expand July 14, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan #ORPH – £3m COVID-19 challenge virus manufacturing contract for hVIVO based on new COVID-19 variants May 9, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan #ORPH – COVID-19 Human Challenge Programme update March 25, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan #ORPH – Ethics approval – COVID-19 Human Challenge Study February 17, 2021 – Posted in: Blog, Open Orphan (ORPH)

Address

Contact

Social

LEGAL